Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) EBITDA: 2012-2016

Historic EBITDA for Tvardi Therapeutics (TVRD) over the last 5 years, with Dec 2016 value amounting to -$57.2 million.

  • Tvardi Therapeutics' EBITDA fell 7.16% to -$12.4 million in Q3 2017 from the same period last year, while for Sep 2017 it was -$65.9 million, marking a year-over-year decrease of 47.04%. This contributed to the annual value of -$57.2 million for FY2016, which is 131.51% down from last year.
  • According to the latest figures from FY2016, Tvardi Therapeutics' EBITDA is -$57.2 million, which was down 131.51% from -$24.7 million recorded in FY2015.
  • Tvardi Therapeutics' EBITDA's 5-year high stood at -$3.1 million during FY2013, with a 5-year trough of -$57.2 million in FY2016.
  • Over the past 3 years, Tvardi Therapeutics' median EBITDA value was -$24.7 million (recorded in 2015), while the average stood at -$33.2 million.
  • As far as peak fluctuations go, Tvardi Therapeutics' EBITDA spiked by 50.74% in 2013, and later tumbled by 477.64% in 2014.
  • Yearly analysis of 5 years shows Tvardi Therapeutics' EBITDA stood at -$6.2 million in 2012, then spiked by 50.74% to -$3.1 million in 2013, then plummeted by 477.64% to -$17.7 million in 2014, then tumbled by 39.34% to -$24.7 million in 2015, then plummeted by 131.51% to -$57.2 million in 2016.